Warfarin or ASA for CHF

In this large randomized trial of patients with systolic CHF and normal sinus rhythm, those randomized to warfarin had lower rates of ischemic stroke (hazard ratio 0.52, CI 0.33 to 0.82), but higher rates of major bleeding (1.8 versus 0.9 events per 100 patient years), compared to ASA. The decision between warfarin and ASA in CHF patients with normal sinus rhythm should be based on risk of stroke and bleeding, without a one-size-fits-all approach (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment